400 Technology Square, 10th Floor
About IFM TherapeuticsIFM Therapeutics is a privately held biopharmaceutical company based in Cambridge, Massachusetts. Seeded by Atlas Venture, the company was founded in 2015 by an international group of preeminent scientists and physicians to discover and develop small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders. Drugs in the IFM portfolio are expected to significantly improve upon standard of care agents in terms of efficacy and safety. For more information, please visit www.ifmthera.com.
CEO: Gary D. Glick
Chief Development Officer: Dennis Dean
Chief Scientific Officer: Shomir Ghosh
36 articles about IFM Therapeutics
IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due
IFM Therapeutics (IFM), today announced that IFM Due, an IFM subsidiary company, has extended its collaboration and exclusive option agreement with Novartis to develop immunotherapies that inhibit the cGAS-STING pathway to treat a range of serious inflammatory and autoimmune diseases.
BioSpace Movers & Shakers, June 5
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
IFM Therapeutics, a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced the appointment of Michael Cooke, Ph.D., as Chief Scientific Officer.
IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer
IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the closing of a $55.5 million financing and the launch of its third subsidiary, IFM Quattro, as well as a new incubator, IFM Discovery, both of which will be supported by a portion of the new funds raised.
IFM Therapeutics is launching its third subsidiary this year with a focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.
New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer's Disease
Study published in Nature by trio of IFM Therapeutics scientists and collaborators demonstrates NLRP3 inflammasome directly drives tau pathology in neurodegenerative diseases and Alzheimer's disease
IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due
Agreement provides funding for research and development costs through late-stage preclinical development of lead program with option to acquire IFM Due
The companies will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre
IFM Therapeutics announced the completion of the previously-announced acquisition of its subsidiary, IFM Tre, by Novartis.
1Q2019 Life Science Growth Announcements
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Acquisition of IFM Therapeutics subsidiary gives Novartis full rights to one clinical and two pre-clinical NLRP3 antagonist programs
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427
Announcement marks first human trial for an NLRP3 antagonist
The drugs target a protein called STING (stimulator of interferon genes), which plays an important role in the innate immune system, which is the body’s first line of defense against various pathogens.
IFM Therapeutics, LLC Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases
World-renowned researcher, Andrea Ablasser, M.D., appointed IFM Due Founding Scientist and named to IFM's Scientific Advisory Board
IFM Therapeutics is launching its second subsidiary in less than a year. This morning, the Boston-based company, launched IFM Due (pronounced du-way), a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases like NASH, lupus and Parkinson’s.
IFM Therapeutics Announces Newly Discovered Mechanism of Inflammatory Processes in the Body
IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the discovery of new immune system triggers that are associated with certain inflammatory diseases.
IFM Scientific Founders Named Among World's Most Influential Researchers
Clarivate Analytics list honors Dr. Luigi Franchi and Dr. Eicke Latz as most highly cited scientists, ranking in the top one percent globally
IFM Therapeutics, LLC Appoints John Leonard, M.D. to Board of Directors
Seasoned industry leader to provide expert counsel to help guide strategic growth of IFM Therapeutics, LLC